Merck sees 57 percent drop in first-quarter profit

Drugmaker Merck posts 57 percent drop in first-quarter profit on lower sales, partner revenue

* Linda A. Johnson, AP Business Writer *

Tuesday April 21, 2009, 8:26 am EDT

TRENTON, N.J. (AP) — Drugmaker Merck & Co. on Tuesday posted a 57 percent drop in first-quarter profit, falling short of expectations, because of a drop in both sales of its drugs and income from its partnership on cholesterol medicines.

full article here

Jupiter study on Statins and heart attack

Although the media blitz will tell you of the great benefits of this toxic chemical, please read the fine print before poisoning yourself for minimal gain.

The “Jupiter” trial was funded by Astra Zeneca (the maker of the drug being tested) to study primary prevention of cardiovascular disease (fatal and nonfatal) in healthy patients with low LDL (<130) yet elevated C reactive protiens (>2.0).

Patients were randomized to receive either rosuvastatin (Crestor) 20mg daily or placebo. After 1.9 years, LDL dropped by 50% and C reactive protiens by 37% in patients on rosuvastatin. In all there were 198 deaths out of 8901 rosuvastatin patients and 247 deaths out of 8901 patients on placebo.

From examination of table 3 of the study (not included here) if you subtract “not fatal myocardial infarction” from “any myocardial infarction,” you find out that there were 9 myocardial infarction (MI) deaths in the rosuvastatin arm and only 6 in the placebo arm. That shows a 50% increase in MI deaths in the arm taking Crestor.

Consider also:

  1. there were 51 more subjects in the placebo arm than in the Rosuvastatin reporting a family history of coronary heart disease.
  2. At the start of the study 71 more subjects in the placebo arm than in the Rosuvastatin arm had metabolic syndrome.
  3. By the end of the study only 75% of subjects had remained compliant. By not reporting which arm of the study the dropouts were from makes any interpretation of adverse reaction inconclusive.
  4. Myopathies were reported to be about equal, which is a highly suspect finding.

Therefore, for every 83 people treated for 1.9 years 1 will benefit. At $3.50 per dose, it would COST $201,000 to benefit that 1 person, not including the additional expenses suffering and deaths incurred from the increased number of patients with statin-induced diabetes.

Low HDL cholesterol is strongly associated with increased Alziemers disease

Too little of HDL (high density lipoprotien), one type of cholesterol, has been linked to memory loss and Alzheimer’s disease.

Scientists studied more than 3,500 civil servants to investigate how levels of HDL or “good” cholesterol were associated with memory. HDL cholesterol can influence the formation of the beta-amyloid “plaques” that are a distinctive feature in the brains of Alzheimer’s patients.

Higher levels of HDL are also believed to protect against damage to blood supply caused by the narrowing of the arteries.

After the five-year study period, the researchers found that people with low levels of HDL were 53 percent more likely to suffer memory loss than people with the highest levels of HDL.

Those with impaired memory are at an increased risk of developing dementia later in life.


Cholesterol Scam

Serum cholesterol does not cause heart disease.  It does hallmark a lifestyle issue that causes heart disease thou.You will find a direct coorelation between consumption of sugar, sweeteners and corn syrup consumption and serum cholesterol.

Taking a Statin does not remove the offending agent, in fact it reduces your bodies ability to defend itself from the free radicals that cause heart disease and as medical research data displays this INCREASES your risk and heart attack and stroke!!  Please feel free to contact me for more information regarding this very important topic.